GL1X · GenesisL1 explorer

MolNFT v1 · #85608 · protein

Parallel screening of a low molecular weight compound library: do differences in methodology affect hit identification

4AHU · Integrase: “Parallel screening of a low molecular weight compound library: do differences in methodology affect hit…”. X-ray diffraction, 3 ligands (ICO, SO4, CL), 7 pockets (best druggability 0.52). MolNFT v1 #85608 on GenesisL1…

PDB
4AHU
Type
protein
Length
306 residues
Chains
2
Method
x-ray diffraction
Collection
MolNFT v1 / PDB
Contract
0xDE3723766Bc32dcACD03C17BaA400A7B36837Eba
Owner
0x3396CDB397284571d12822B4ae1189a8E22AAAAA
Molecule
Integrase
EC
2.7.7.1
UniProt
P12497
Ligands
ICO, SO4, CL
Pockets
7 · best druggability 0.52

Structure

x-ray diffraction · 2 distinct chains · 49% helix, 21% strand (DSSP).

ChainMoleculeTypeResiduesSecondary structureUniProt
AIntegrase (EC 2.7.7.1)protein15349% helix, 21% strandP12497
BIntegrase (EC 2.7.7.1)protein15350% helix, 21% strandP12497

Ligands and binding sites

  • ICO · 1H-indole-3-carboxylic acid · ligand · 2 copies · chains A, B
  • SO4 · Sulfate ion · ion · 6 copies · chains A, B
  • CL · Chloride ion · ion · 2 copies · chains A, B
  • GOL · Glycerol · additive · 4 copies · chains A, B
  • ACY · Acetic acid · additive · chains B
  • EDO · 1,2-ethanediol · additive · chains A, B

Binding sites are the residues within 4.5 Å of a ligand's heavy atoms.

Pockets

7 pockets found on a 1 Å grid, 2 with a druggability of 0.5 or more.

PocketVolume (ų)DruggabilityBuriednessLining residuesInside
11200.520.8126ICO
21290.520.8125ICO
32320.490.7539empty
41590.480.7720empty
51210.480.7917SO4, GOL

Interfaces

1 interface between chains.

  • A–B · 1455 Ų buried · 17 hydrogen bonds · protein-protein

Compared structures

  • 4AHU · Parallel screening of a low molecular weight compound library: do differences in… · the same entry in another collection · chain A against A, TM-score 1.00

Analyse

GL1X is a live explorer of the GenesisL1 blockchain. Turn on JavaScript for search, charts and interactive views.